By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agendia BV 

Slotervaart Medical Centre, 9D
Louwesweg 6
Amsterdam    1066 EC  The Netherlands
Phone: 31-20-512-9161 Fax: 31-20-512-9162


SEARCH JOBS


Industry
Services
Healthcare






Company News
Agendia BV Appoints Patrick J. Balthrop Sr., Former CEO Of Luminex (LMNX), As Chairman 4/20/2017 11:24:21 AM
Agendia BV Appoints Patrick J. Balthrop Sr., Former CEO Of Luminex (LMNX), As Chairman 4/13/2017 7:21:39 AM
European Group On Tumour Markers (EGTM) Updated Guidelines Recommend Agendia BV's Mammaprint Test With Highest Level 1A Clinical Evidence 3/22/2017 6:47:32 AM
European Group On Tumour Markers (EGTM) Updated Guidelines Recommend Agendia BV’s Mammaprint Test With Highest Level 1A Clinical Evidence 3/21/2017 8:42:18 AM
Agendia BV Release: German Community Of Gynecological Oncology (AGO) Acknowledges Mammaprint In Breast Cancer Guidelines As Having Level 1A Clinical Evidence 3/8/2017 6:56:29 AM
Agendia BV Co-Founder Laura van ’t Veer Wins European Cancer Organization Clinical Research Award 1/30/2017 8:48:43 AM
Agendia BV Release: New Data Shows That MammaPrint Substantially Impacts How Breast Cancer Patients In Germany Are Treated 12/21/2016 9:26:54 AM
Agendia BV Release: Three New Studies Presented At San Antonio Breast Cancer Symposium Further Demonstrate Value Of Mammaprint And Blueprint In Individualizing Treatment For Breast Cancer Patients 12/14/2016 7:42:29 AM
Agendia BV’s Mammaprint And Blueprint Tests Highlighted In Multiple Presentations At The 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility 12/2/2016 9:03:18 AM
Agendia BV's Proven Breast Cancer Recurrence Assay, MammaPrint, Now Available In The Middle East 11/8/2016 10:01:23 AM
12345678910...
//-->